Rachel Rosenzweig1,2, Vinay Kumar1,2, Sahil Gupta1,2, Oscar Bermeo-Blanco1,2, Matthew S Stratton1,2, Richard J Gumina1,2,3, Shyam S Bansal1,2,3. 1. Department of Physiology and Cell Biology (R.R., V.K., S.G., O.B.-B., M.S.S., R.J.G., S.S.B.), The Ohio State University Wexner Medical Center, Columbus. 2. The Dorothy M. Davis Heart & Lung Research Institute (R.R., V.K., S.G., O.B.-B., M.S.S., R.J.G., S.S.B.), The Ohio State University Wexner Medical Center, Columbus. 3. Division of Cardiovascular Medicine, Department of Internal Medicine (R.J.G., S.S.B.), The Ohio State University Wexner Medical Center, Columbus.
Abstract
BACKGROUND: CD4+ T cells temporally transition from protective to pathological during ischemic heart failure (HF; 8 weeks postmyocardial infarction). Cellular mechanisms mediating this shift are unknown. METHODS: RNA-sequencing of cardiac CD4+ T cells and flow cytometric analysis of immune cells was conducted. RESULTS: RNA-sequencing of CD4+ T cells from the failing hearts of male mice indicated activation of ER (estrogen receptor)-α signaling. Flow cytometric analysis showed that ERα in CD4+ T cells decreases significantly at 3-day postmyocardial infarction but increases during HF. To antagonize ERα, we tested a novel ERβ agonist (OSU-ERb-012) to inhibit T cells and blunt left ventricular remodeling. Proliferation assays showed that OSU-ERb-012 dose-dependently inhibited proliferation and proinflammatory cytokine expression in anti-CD3/CD28 stimulated splenic T cells isolated from both the sexes. For in vivo efficacy, 10- to 12-week-old male and ovariectomized female mice were randomized at 4 weeks postmyocardial infarction and treated with either vehicle or drug (60 mg/kg per day; oral). While vehicle-treated HF mice displayed progressive left ventricular dilatation with significantly increased end-systolic and end-diastolic volumes from 4 to 8 weeks postmyocardial infarction, treatment with OSU-ERb-012 significantly blunted these changes and stopped left ventricular remodeling in both the sexes. Reduction in tibia-normalized heart and left ventricular weights, cardiomyocyte hypertrophy and interstitial fibrosis further supported these results. Additionally, OSU-ERb-012 treatment selectively inhibited cardiac, splenic, and circulating CD4+ T cells without affecting other myeloid and lymphoid cells in the HF mice. CONCLUSIONS: Our studies indicate that ERβ agonists and OSU-ERb-012, in particular, could be used as selective immunomodulatory drugs to inhibit CD4+ T cells during chronic HF.
BACKGROUND: CD4+ T cells temporally transition from protective to pathological during ischemic heart failure (HF; 8 weeks postmyocardial infarction). Cellular mechanisms mediating this shift are unknown. METHODS: RNA-sequencing of cardiac CD4+ T cells and flow cytometric analysis of immune cells was conducted. RESULTS: RNA-sequencing of CD4+ T cells from the failing hearts of male mice indicated activation of ER (estrogen receptor)-α signaling. Flow cytometric analysis showed that ERα in CD4+ T cells decreases significantly at 3-day postmyocardial infarction but increases during HF. To antagonize ERα, we tested a novel ERβ agonist (OSU-ERb-012) to inhibit T cells and blunt left ventricular remodeling. Proliferation assays showed that OSU-ERb-012 dose-dependently inhibited proliferation and proinflammatory cytokine expression in anti-CD3/CD28 stimulated splenic T cells isolated from both the sexes. For in vivo efficacy, 10- to 12-week-old male and ovariectomized female mice were randomized at 4 weeks postmyocardial infarction and treated with either vehicle or drug (60 mg/kg per day; oral). While vehicle-treated HF mice displayed progressive left ventricular dilatation with significantly increased end-systolic and end-diastolic volumes from 4 to 8 weeks postmyocardial infarction, treatment with OSU-ERb-012 significantly blunted these changes and stopped left ventricular remodeling in both the sexes. Reduction in tibia-normalized heart and left ventricular weights, cardiomyocyte hypertrophy and interstitial fibrosis further supported these results. Additionally, OSU-ERb-012 treatment selectively inhibited cardiac, splenic, and circulating CD4+ T cells without affecting other myeloid and lymphoid cells in the HF mice. CONCLUSIONS: Our studies indicate that ERβ agonists and OSU-ERb-012, in particular, could be used as selective immunomodulatory drugs to inhibit CD4+ T cells during chronic HF.
Authors: Meijing Wang; Paul Crisostomo; George M Wairiuko; Daniel R Meldrum Journal: Am J Physiol Heart Circ Physiol Date: 2006-01-13 Impact factor: 4.733
Authors: Shokoufeh Mahmoodzadeh; Sarah Eder; Johannes Nordmeyer; Elisabeth Ehler; Otmar Huber; Peter Martus; Jörg Weiske; Reinhard Pregla; Roland Hetzer; Vera Regitz-Zagrosek Journal: FASEB J Date: 2006-05 Impact factor: 5.191
Authors: Njabulo Ngwenyama; Annet Kirabo; Mark Aronovitz; Francisco Velázquez; Francisco Carrillo-Salinas; Ane M Salvador; Tania Nevers; Venkataraman Amarnath; Albert Tai; Robert M Blanton; David G Harrison; Pilar Alcaide Journal: Circulation Date: 2021-01-19 Impact factor: 29.690
Authors: Logan A Walker; Michael G Sovic; Chi-Ling Chiang; Eileen Hu; Jiyeon K Denninger; Xi Chen; Elizabeth D Kirby; John C Byrd; Natarajan Muthusamy; Ralf Bundschuh; Pearlly Yan Journal: J Transl Med Date: 2020-02-10 Impact factor: 5.531
Authors: Matthias Nahrendorf; Filip K Swirski; Elena Aikawa; Lars Stangenberg; Thomas Wurdinger; Jose-Luiz Figueiredo; Peter Libby; Ralph Weissleder; Mikael J Pittet Journal: J Exp Med Date: 2007-11-19 Impact factor: 14.307